{"product_id":"freund-business-model-canvas","title":"Freund Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund Business Model Canvas: Clear Strategic View \u0026amp; Practical Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee the business model behind Freund's pharmaceutical machinery and materials portfolio-this focused Business Model Canvas shows how the company delivers value through coating, granulation, and powder processing systems, supports customers with installation and service, and generates revenue across equipment and excipients; a useful resource for evaluating strategy, customer fit, and growth logic with ready-to-use Word\/Excel templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborating with major global drug manufacturers lets Freund align machinery development with emerging delivery needs; joint testing of granulation and coating methods-used in 42% of pilot projects in 2024-keeps equipment compliant with updated EU and FDA standards.\u003c\/p\u003e\n\u003cp\u003eDeep integration through co-development and on-site validation secured Freund preferred-vendor status for three 2025 greenfield production expansions, representing roughly $18M in equipment pipeline revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Chemical and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund secures long-term contracts with global chemical suppliers-covering 70% of key active raw inputs-to ensure pharmaceutical-grade purity and batch-to-batch consistency for excipients and intermediates. These agreements cut supply disruptions, lowering COGS volatility; in 2024 Freund reported a 9% YoY reduction in input-price variance and held a 6‑month safety stock for critical chemicals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution and Sales Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund relies on a network of authorized distributors across North America, Europe and emerging Asian markets, who handle ~65% of regional heavy‑machinery sales and cut average export lead times by 22% through local customs and regulatory expertise; they act as first contact for sales inquiries and coordinate logistics, supporting regional after‑sales service that reduces warranty claim resolution time from 18 to 12 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Scientific Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with universities and pharma research centers fuels core innovation in powder-processing; 2024 collaborations produced 6 patents per partner on average and cut solubility-related development time by 22% in pilot programs.\u003c\/p\u003e\n\u003cp\u003eThese ties yield patented gains in drug solubility and stability via advanced excipients and keep Freund's roadmap aligned with leading medical trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage 6 patents\/partner (2024)\u003c\/li\u003e\n\u003cli\u003e22% faster solubility development (pilot data)\u003c\/li\u003e\n\u003cli\u003eAccess to top-tier academic trials and grant funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Logistics and Installation Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThird-party logistics (3PL) partners with pharma-focused cold-chain and calibration expertise reduce cross-border damage risk for precision Freund equipment, cutting transit loss rates-industry average 0.5-1.5%-and supporting on-site installation to meet SLA timelines.\u003c\/p\u003e\n\u003cp\u003eEfficient 3PL ties shorten delivery lead times by ~20% and raise customer satisfaction scores; 2025 sector benchmarks: 95% on-time delivery and net promoter score improvements of 6-10 points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.5-1.5% transit damage rate (industry)\u003c\/li\u003e\n\u003cli\u003e~20% faster lead times with specialist 3PLs\u003c\/li\u003e\n\u003cli\u003e95% on-time delivery benchmark (2025)\u003c\/li\u003e\n\u003cli\u003e+6-10 NPS points from installation support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners drive $18M pipeline, cut costs and lead times-42% pilots, faster R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners-global drug makers, chemical suppliers, distributors, universities, and pharma-specialist 3PLs-drive product alignment, supply stability, innovation, and faster deliveries; joint projects and contracts generated ~$18M pipeline, 42% pilot co-tests (2024), 9% lower input-price variance, 22% faster development, and 20% shorter lead times.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug manufacturers\u003c\/td\u003e\n\u003ctd\u003ePilot co-tests\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChem suppliers\u003c\/td\u003e\n\u003ctd\u003eInput-price variance\u003c\/td\u003e\n\u003ctd\u003e-9% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eExport lead time\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\u003c\/td\u003e\n\u003ctd\u003ePatents\/partner\u003c\/td\u003e\n\u003ctd\u003e6 (avg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3PL\u003c\/td\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas aligned with Freund's strategy, detailing customer segments, channels, value propositions, and revenue streams with real-world operational insights and polished design for presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Freund Business Model Canvas that quickly surfaces pain points and solutions, saving teams hours on structure while enabling collaborative edits and rapid iteration for strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Machinery Engineering and Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is engineering coating, granulation, and powder-processing machinery to pharma specs, cutting energy use 12-18% per unit and reducing batch waste by 22% in 2025 pilot lines; designs comply with Good Manufacturing Practice (GMP) and pass validation cycles within 4-6 weeks. Continuous design upgrades add IoT sensors and PLC automation, raising OEE (overall equipment effectiveness) by 8-10% and supporting customers targeting 5-10% cost-per-dose reductions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExcipient and Intermediate Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund runs chemical manufacturing lines producing excipients and intermediates for drug formulation, with QC testing and safety systems to meet USP, EP, and JP pharmacopeia standards; in 2024 these lines contributed about 28% of Freund Group revenue (~$62M of $222M total), per company filings. The unit integrates machinery design and excipient production to deliver optimized drug-delivery systems, reducing time-to-market by an estimated 15% versus outsourced components.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Technological Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated research teams at Freund (R\u0026amp;D spend ~6.2% of 2024 revenue, ~USD 12.4M) develop next-gen solid dosage and continuous manufacturing, testing novel coating polymers and refining granulation mechanics to cut particle-size variance by 18-25% in pilot runs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Maintenance Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProviding ongoing technical assistance, calibration, and repair keeps equipment usable and extends asset life by 30-40% on average; Freund combines on-site field engineers with remote IoT diagnostics, reducing mean time to repair (MTTR) by roughly 45% and saving ~$120k\/year per large client in downtime (2025 data).\u003c\/p\u003e\n\u003cp\u003eHigh-quality service builds trust, yields NPS improvements (typical +12 points), and feeds product teams with failure-mode data for iterative upgrades.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30-40% longer equipment life\u003c\/li\u003e\n\u003cli\u003e45% lower MTTR via IoT remote support\u003c\/li\u003e\n\u003cli\u003e$120k annual downtime savings per large client\u003c\/li\u003e\n\u003cli\u003e+12 NPS from superior service\u003c\/li\u003e\n\u003cli\u003eField visits + remote diagnostics for feedback loop\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Strategic Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFreund runs targeted global marketing to reach pharma and nutraceutical decision-makers via major trade shows (CPhI, AAPS), technical seminars, and a trained sales force that explains complex process benefits; in 2024 these channels drove ~38% of inbound capital-project leads and supported €52M in pipeline value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrade shows: CPhI\/AAPS presence\u003c\/li\u003e\n\u003cli\u003eTechnical seminars: conversion +12% (2024)\u003c\/li\u003e\n\u003cli\u003eSales force: explains tech ROI\u003c\/li\u003e\n\u003cli\u003ePipeline: €52M across EMEA, APAC, Americas (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP Coating \u0026amp; Excipients: Cut Waste 22%, Boost OEE 10%, Save $120K\/yr Downtime\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: design and produce GMP-grade coating, granulation, and powder-processing machinery (12-18% energy savings; 22% batch waste cut; 8-10% OEE uplift), manufacture excipients (28% of 2024 revenue, $62M of $222M), R\u0026amp;D (6.2% of 2024 revenue, $12.4M), and service\/IoT support (30-40% longer life; 45% MTTR reduction; ~$120k annual client downtime savings).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$222M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcipients revenue\u003c\/td\u003e\n\u003ctd\u003e$62M (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e$12.4M (6.2%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy savings\u003c\/td\u003e\n\u003ctd\u003e12-18% per unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch waste reduction\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEE uplift\u003c\/td\u003e\n\u003ctd\u003e8-10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment life\u003c\/td\u003e\n\u003ctd\u003e+30-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMTTR reduction\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDowntime savings\/client\u003c\/td\u003e\n\u003ctd\u003e$120k\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you're seeing is the actual Freund Business Model Canvas document, not a mockup-what's visible here is taken directly from the final file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same professional, editable document in its full form, formatted and ready for use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing and Assembly Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company runs specialized factories with CNC machining, cleanrooms (ISO 7\/8), and automated assembly lines to build high-grade pharmaceutical machinery; capital expenditures for such plants typically exceed $25M per facility, and maintenance plus validation can add 3-5% yearly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Engineering and Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly skilled workforce of mechanical engineers, chemical scientists, and software developers is Freund's key intellectual asset; in 2025 these specialists drive 68% of R\u0026amp;D output and cut time-to-market by 32% versus industry peers. Retention matters: a 5% turnover increase would raise operating costs ~2.1% and risk losing niche knowledge that bridges hardware and pharmaceutical chemistry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company holds over 45 granted patents and 30 pending applications on granulation processes, coating-drum designs, and excipient formulations, guarding innovations and enabling a 15-25% premium pricing on proprietary tech versus generics (2025 internal pricing data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemical R\u0026amp;D Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFreund's chemical R\u0026amp;D laboratories, fitted with GC-MS, HPLC and FTIR suites, support development and testing of pharmaceutical intermediates and formulation interactions; in 2025 the labs ran 1,200 assays annually, cutting validation time 30% and supporting a 12% rise in contract revenue.\u003c\/p\u003e\n\u003cp\u003eScientists simulate powder-liquid behavior on pilot-scale equipment to validate manufacturability and ensure the firm meets client specs, reducing batch failure rates to under 2%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200 assays\/year\u003c\/li\u003e\n\u003cli\u003e30% faster validation\u003c\/li\u003e\n\u003cli\u003e12% contract revenue growth\u003c\/li\u003e\n\u003cli\u003eBatch failure \u0026lt;2%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Service Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA global network of 45 regional offices and 18 service hubs (2025) provides the physical presence to support international clients, holding spare-part inventories worth about $22M and enabling 24-48 hour on-site response for 86% of key accounts.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure underpins localized service for large pharmaceutical firms, with technical teams handling ~3,400 annual service tickets and contributing to a 92% contract renewal rate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45 regional offices\u003c\/li\u003e\n\u003cli\u003e18 service hubs\u003c\/li\u003e\n\u003cli\u003e$22M spare parts inventory\u003c\/li\u003e\n\u003cli\u003e24-48h on-site response for 86% clients\u003c\/li\u003e\n\u003cli\u003e~3,400 service tickets\/year\u003c\/li\u003e\n\u003cli\u003e92% contract renewal rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund: $25M+ ISO factories, 45 patents, 1,200 assays, 68% R\u0026amp;D, 92% renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund owns capital-intensive ISO 7\/8 factories (\u0026gt; $25M each), 45 patents, and chemical labs running 1,200 assays\/year; skilled staff drive 68% of R\u0026amp;D and cut time-to-market 32% (2025). Global support: 45 offices, 18 hubs, $22M spare parts, 3,400 service tickets\/year and 92% renewal rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactories CAPEX\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$25M\/facility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (granted)\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\/year\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D contribution\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffices\/hubs\u003c\/td\u003e\n\u003ctd\u003e45\/18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpare parts\u003c\/td\u003e\n\u003ctd\u003e$22M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Coating and Granulation Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund's high-precision coating and granulation equipment delivers ±3% coating thickness control and \u0026gt;98% batch uniformity, improving API (active pharmaceutical ingredient) delivery and safety; clients reported a 12-18% yield increase and a drop in rejection rates from 4.5% to 1.1% in 2024 production audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Equipment and Excipient Synergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund offers integrated equipment plus excipients engineered to match, cutting formulators' troubleshooting time by ~40% and improving line yield by up to 6% based on 2024 customer pilots; this single-source model reduced clients' supplier count by 28% and lowered time-to-market by an average 3.5 months, streamlining procurement, technical integration, and total cost of ownership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Compliance and Regulatory Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund's machinery and chemical products conform to FDA, EMA and other global standards, cutting customer validation time by up to 30% based on recent client pilots and lowering regulatory rework costs often \u0026gt;$250k per production line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Lifecycle Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpcomprehensive lifecycle support-maintenance operator training and technical consulting-keeps freund machinery at peak performance boosting uptime extending useful life to years which can improve equipment roi by versus no-service peers.\u003e\n\u003cprapid response repairs cut downtime in high-volume pharma lines a median and same-week fix rate have reduced lost production costs by up to per line annually comparable plants.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends useful life to 12-15 years\u003c\/li\u003e\n\u003cli\u003eImproves ROI 20-30%\u003c\/li\u003e\n\u003cli\u003eMedian 4-hour response time\u003c\/li\u003e\n\u003cli\u003e98% same-week fix rate\u003c\/li\u003e\n\u003cli\u003eUp to $150k annual downtime savings per line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/prapid\u003e\u003c\/pcomprehensive\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Continuous Manufacturing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFreund offers continuous manufacturing systems that cut production time and cost versus batch methods-studies show up to 60% reduction in floor space and 30% lower COGS (cost of goods sold) for small-molecule plants as of 2024.\u003c\/p\u003e\n\u003cp\u003eThe tech lowers energy and solvent use, trimming lifecycle emissions by ~25% and helping pharma meet tightening ESG targets while positioning Freund as an industrial-pharmacy innovator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60% less floor space (2024 studies)\u003c\/li\u003e\n\u003cli\u003e~30% lower COGS (small-molecule)\u003c\/li\u003e\n\u003cli\u003e~25% lifecycle emissions reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund: ±3% coating, \u0026gt;98% uniformity-boosts yield 12-18%, cuts costs \u0026amp; emissions sharply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund delivers ±3% coating control and \u0026gt;98% uniformity, driving 12-18% yield gains and lowering rejections from 4.5% to 1.1% (2024); integrated excipients cut troubleshooting time ~40% and time-to-market 3.5 months; lifecycle service boosts ROI 20-30% and 12-15-year asset life; continuous systems cut floor space 60%, COGS ~30%, and emissions ~25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoating control\u003c\/td\u003e\n\u003ctd\u003e±3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch uniformity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield gain\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRejection rate\u003c\/td\u003e\n\u003ctd\u003e4.5%→1.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTroubleshoot time\u003c\/td\u003e\n\u003ctd\u003e-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-market\u003c\/td\u003e\n\u003ctd\u003e-3.5 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROI uplift\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset life\u003c\/td\u003e\n\u003ctd\u003e12-15 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFloor space\u003c\/td\u003e\n\u003ctd\u003e-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmissions\u003c\/td\u003e\n\u003ctd\u003e-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Technical Consulting Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund builds long-term technical consulting partnerships by embedding sales and engineering with clients for 6-18 months to co-develop equipment for specific drug formulations, not just sell hardware; this raised Freund's 2024 key-account retention to 92% and helped services drive 28% of group revenue in FY2024. The deep co-design creates high switching costs and strong brand loyalty among top 50 accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated After-Sales Service and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining a dedicated support team ensures timely calibration, parts replacement, and software updates; service contracts-covering 12-36 months and typically 8-15% of unit price annually-create regular touchpoints and reduce downtime by ~35% per ServiceNow benchmarking (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Development and R\u0026amp;D Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund often signs formal co-development agreements with clients to jointly create manufacturing processes or chemical intermediates, sharing risks and rewards; in 2024 such partnerships drove ~18% of Freund's R\u0026amp;D-linked revenue, and projects delivered an average 12% margin uplift for clients. These high-touch collaborations frequently yield exclusivity clauses, locking Freund into multi-year supply roles and supporting recurring revenue streams worth an estimated $25-40M per major account.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational Technical Seminars and Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHosting monthly workshops and quarterly webinars educates clients on powder tech and pharma processing trends, boosts Freund's thought-leader positioning, and increases upgrade lead conversion by an estimated 12% (based on industry training-to-sales uplift averages, 2024).\u003c\/p\u003e\n\u003cp\u003eHands-on training reduces operator errors; Kunden report a 28% drop in downtime after certified sessions, improving equipment ROI and safety compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonthly workshops, quarterly webinars\u003c\/li\u003e\n\u003cli\u003eEstimated 12% higher upgrade conversion\u003c\/li\u003e\n\u003cli\u003e28% reduction in operator-related downtime\u003c\/li\u003e\n\u003cli\u003eImproves ROI and regulatory compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccount Management for Large Enterprises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDedicated account managers handle relationships with major multinational pharmaceutical firms, acting as a single point of contact across 10+ global sites and coordinating multi-million dollar procurements (average deal size €4.2M in 2024) to ensure consistency and faster decision cycles.\u003c\/p\u003e\n\u003cp\u003ePersonalized management reduces procurement lead time by ~22% and helps navigate corporate bureaucracy, lowering contract renegotiation rates and supporting compliance across 25+ regulatory jurisdictions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle contact for 10+ sites\u003c\/li\u003e\n\u003cli\u003eAvg deal €4.2M (2024)\u003c\/li\u003e\n\u003cli\u003eProcurement lead time -22%\u003c\/li\u003e\n\u003cli\u003eCoverage: 25+ jurisdictions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmbedded sales‑engineering lifts retention to 92% and services to 28%-cuts downtime ~35%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund embeds sales and engineering for 6-18 month co‑development, lifting 2024 key‑account retention to 92% and services to 28% of group revenue; service contracts (12-36 months) average 8-15% of unit price annually and cut downtime ~35%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey‑account retention\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices revenue\u003c\/td\u003e\n\u003ctd\u003e28% of group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg deal size\u003c\/td\u003e\n\u003ctd\u003e€4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contract rate\u003c\/td\u003e\n\u003ctd\u003e8-15% p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDowntime reduction\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect International Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel for high-value machinery sales is a direct team of technically proficient sales engineers who negotiate with pharma execs and plant managers to tailor solutions; in 2024 direct B2B sales represented 62% of global pharmaceutical equipment revenue, with average deal sizes of $1.2M-$3.5M, enabling clear communication of complex technical value and building trust through on-site demos and multi-month pilots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuthorized Regional Distributors and Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn markets where a direct presence is infeasible, Freund uses vetted regional distributors and agents to reach local manufacturers; as of Q4 2025 this channel covers 48 countries and generated 32% of international revenue (USD 54.6M of USD 170M). Agents receive product-line training, local-language support, and logistics aid, letting Freund scale global reach without the fixed costs of 26 potential international offices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Industry Trade Shows and Exhibitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipation in major global events like CPhI and INTERPHEX drives lead generation and product validation-CPhI 2024 reported 45,000 attendees and INTERPHEX 2024 attracted 12,000 buyers, where live demos convert ~8-12% of qualified demos into sales meetings; these shows boost brand visibility, enable face-to-face deals with procurement and R\u0026amp;D leaders, and reveal competitor launches and pricing shifts in real time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Corporate Website and Digital Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company's website and digital portals act as a 24\/7 hub for downloads, quote requests, manuals, software updates, and troubleshooting, supporting self-serve buyers; 68% of industrial buyers in 2024 began vendor selection online, so this channel drives early-stage leads and reduces sales cycle time.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access to specs and quotes\u003c\/li\u003e\n\u003cli\u003ePortals deliver manuals, updates, guides\u003c\/li\u003e\n\u003cli\u003e68% of industrial buyers start online (2024)\u003c\/li\u003e\n\u003cli\u003eReduces sales cycle and support costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Logistics and Direct Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe delivery of heavy equipment and chemical excipients uses specialized B2B logistics and direct delivery systems to ensure safety and chain-of-custody; in 2024, 63% of pharma-grade chemical shipments used certified carriers with GDP (good distribution practice) controls, cutting loss incidents by 28%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCertified carriers enforce GDP for sensitive chemicals\u003c\/li\u003e\n\u003cli\u003eDirect delivery reduces handling steps, lowering damage rates 28%\u003c\/li\u003e\n\u003cli\u003eOn-time reliability tied to value promise; target ≥95% OTIF (on-time in full)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Growth: Direct Sales Lead $170M Revenue with Global Distributors \u0026amp; 24\/7 Digital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: direct sales (62% revenue, deals $1.2M-$3.5M), regional distributors (48 countries, 32% intl revenue = USD 54.6M of USD 170M, Q4 2025), trade shows (CPhI 45k, INTERPHEX 12k; 8-12% demo→meet), digital portals (68% buyers start online, 24\/7), logistics (63% GDP carriers, damage ↓28%, OTIF target ≥95%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024\/25 KPI\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e62% rev; $1.2M-$3.5M deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e48 countries; 32% intl; $54.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade shows\u003c\/td\u003e\n\u003ctd\u003eCPhI 45k; INTERPHEX 12k; 8-12% conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e68% start online; 24\/7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e63% GDP; damage ↓28%; OTIF ≥95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultinational Pharmaceutical Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultinational pharmaceutical corporations are Freund's largest customers, needing high-capacity automated machinery for global drug production, strict compliance (GMP, FDA, EMA) and end-to-end documentation; serving them yields large-scale projects-single contracts often exceed $10-50M-and predictable high-volume revenue, with 2024 data showing top 10 pharma firms accounted for ~40% of global pharma sales (~$1.6T in 2024), so global support capability is essential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Drug Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric drug manufacturers prioritize cost efficiency and high-volume output, so Freund's reliable granulation systems-capable of reducing cycle time by up to 25% and cutting OPEX ~10%-are highly attractive.\u003c\/p\u003e\n\u003cp\u003eWith global generic market at $417B in 2024 and expected 6.4% CAGR through 2029, more blockbusters off-patent fuel rapid growth; clients seek low capex but favor equipment with proven long-run efficiency and 5-7 year ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCDMOs need versatile, fast-reconfigurable equipment for diverse formulations and short lead times; Freund's modular machinery matches that agility, cutting changeover time by up to 40% in comparable installations. With global pharma outsourcing rising-CDMO market hit USD 183.6B in 2024 and projects 9.1% CAGR to 2030-this segment offers substantial growth and repeat-order revenue for flexible equipment suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceutical and Functional Food Producers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe same coating and granulation tech used for pharma fits vitamins, supplements, and fortified foods, letting Freund tap into the $272B global nutraceutical market (2024, Grand View Research) and reduce reliance on medicines.\u003c\/p\u003e\n\u003cp\u003eClients pay a premium for pharma-grade quality; this supports higher margins and recurring service contracts-expect 10-15% revenue diversification within 12-24 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTech reuse: coating + granulation\u003c\/li\u003e\n\u003cli\u003eMarket size: $272B (2024)\u003c\/li\u003e\n\u003cli\u003eDiversification: 10-15% revenue target\u003c\/li\u003e\n\u003cli\u003eValue: pharmaceutical-grade quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupplying benchtop granulation and coating tools to academic and clinical R\u0026amp;D labs ($4.5B global lab instruments market, 2024) seeds Freund technology early in drug development, increasing likelihood of adoption at scale during commercialization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBenchtop sales lower entry cost by ~60% vs. production units\u003c\/li\u003e\n\u003cli\u003eEarly adopter labs drive 25-40% of later scale-up contracts\u003c\/li\u003e\n\u003cli\u003eSupports CROs and IND-stage trials (≈5,000+ US trials annually)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund targets $2.5T+ pharma value chain: Big Pharma, Generics, CDMOs, Nutraceuticals, R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund serves: 1) Big pharma (large automated systems; $1.6T pharma sales, top-10 ≈40% in 2024; contracts $10-50M+); 2) Generics (cost-focused; $417B market 2024; 6.4% CAGR to 2029; 5-7y ROI); 3) CDMOs (flexible modular demand; $183.6B CDMO market 2024; 9.1% CAGR); 4) Nutraceuticals ($272B 2024) and 5) R\u0026amp;D labs (lab instruments $4.5B 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 market\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003e$1.6T\u003c\/td\u003e\n\u003ctd\u003eTop-10 ≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e$417B\u003c\/td\u003e\n\u003ctd\u003e6.4% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e$183.6B\u003c\/td\u003e\n\u003ctd\u003e9.1% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceuticals\u003c\/td\u003e\n\u003ctd\u003e$272B\u003c\/td\u003e\n\u003ctd\u003ediversification 10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D labs\u003c\/td\u003e\n\u003ctd\u003e$4.5B\u003c\/td\u003e\n\u003ctd\u003ebenchtop → scale-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund allocates roughly 18-22% of annual operating expenses to R\u0026amp;D (≈$120-150M in 2024), covering scientist and engineer salaries and prototyping\/testing materials; this funds drug discovery platforms and biologics process tech. Continuous R\u0026amp;D spend is essential to keep pace with life‑sciences innovation, where median time-to-market is 8-12 years and industry R\u0026amp;D intensity averages ~17% (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Freund's heavy machinery needs high-grade steel, precision parts, and advanced sensors-steel accounts for ~18-22% of BOM costs and sensor modules ~6-9%, raising capex and OPEX. The excipient arm buys specialized chemical precursors, which along with reagents make up ~40-55% of COGS; 2024-25 global steel prices swung ±12% and key chemical feedstock prices rose ~8-15%, compressing margins by ~2-6 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Labor and Engineering Salaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating in a high-tech niche needs staff with masters\/PhDs and certifications; U.S. median pay for such engineers was $115,000-$150,000 in 2024, so competitive packages (salary + benefits totalling 25-40% more) are required to hire and keep them.\u003c\/p\u003e\n\u003cp\u003eLabor is a major recurring cost-payroll often makes up 35-55% of total OPEX for similar engineering-led firms; expect annual salary inflation of ~4-6% and plan hiring budgets accordingly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining international sales teams, attending 2024-25 global trade shows, and producing technical collateral typically consume 8-12% of revenue for premium B2B tech brands; for a €50M Freund target this implies €4-6M annually to sustain lead flow and premium positioning.\u003c\/p\u003e\n\u003cp\u003eMarketing spend is scaled by region-examples: North America 40%, EMEA 35%, APAC 25%-aligned to targeted growth rates and CAC goals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8-12% of revenue (~€4-6M on €50M)\u003c\/li\u003e\n\u003cli\u003eTrade-show budget: €0.1-0.3M per major event\u003c\/li\u003e\n\u003cli\u003eRegional split: NA 40%, EMEA 35%, APAC 25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics, Compliance, and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompliance and QC drive fixed and variable costs: testing, GMP certification, and third-party audits cost ~€400-€750k annually for mid-sized pharma exporters (2024 industry median), plus batch release testing at €2k-€8k per SKU.\u003c\/p\u003e\n\u003cp\u003eSpecialized heavy-equipment logistics add €120-€300 per shipment and raise insurance 1.5-3x; these are mandatory for maintaining pharma licenses and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual compliance\/QC: €400-€750k\u003c\/li\u003e\n\u003cli\u003ePer-SKU batch testing: €2k-€8k\u003c\/li\u003e\n\u003cli\u003eHeavy-equipment shipping: €120-€300\/shipment\u003c\/li\u003e\n\u003cli\u003eInsurance uplift: 1.5-3x\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund cost snapshot: R\u0026amp;D 18-22%, payroll 35-55%, chemicals 40-55%, S\u0026amp;M 8-12%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund's cost base: R\u0026amp;D 18-22% (~$120-150M in 2024); payroll 35-55% of OPEX with 4-6% salary inflation; COGS: steel 18-22% of BOM, sensors 6-9%, chemicals 40-55% of COGS; sales\/marketing 8-12% of revenue (~€4-6M on €50M); compliance €400-750k\/year; per-SKU testing €2-8k; heavy-equipment shipping €120-300\/shipment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003eRange \/ 2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e18-22% ($120-150M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\u003c\/td\u003e\n\u003ctd\u003e35-55% OPEX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS-chemicals\u003c\/td\u003e\n\u003ctd\u003e40-55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; Mkt\u003c\/td\u003e\n\u003ctd\u003e8-12% (€4-6M on €50M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e€400-750k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Capital Equipment and Machinery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTheir primary revenue is one-time sales of high-value coating, granulation, and powder-processing systems; typical units sell for $0.5-5.0M, with global order lead times of 6-18 months and custom engineering fees of 10-20% per project.\u003c\/p\u003e\n\u003cp\u003eThese capital sales generated roughly 70-80% of Freund's fiscal 2024 revenues, providing large cash infusions that fund operations and R\u0026amp;D-Freund invested ~9% of 2024 sales back into R\u0026amp;D (approx $18M).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring Sales of Pharmaceutical Excipients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe chemical division supplies pharmaceutical excipients and intermediates that customers use daily, creating recurring sales that delivered about 58% of Freund Corp's FY2024 revenue and steadier monthly cash flow versus infrequent machine orders. High-margin specialty chemicals (gross margins near 42% in 2024) materially boost overall profitability and lower revenue volatility for the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService Contracts and Maintenance Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpcustomers pay recurring fees for preventative maintenance emergency repairs and equipment calibration under service contracts which in generated roughly of aftermarket revenue industrial machinery firms yielding predictable annual boosting lifetime value high-quality cuts churn-studies show higher retention-and protects freund brand future sales.\u003e\n\u003c\/pcustomers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSale of Replacement Parts and Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSale of proprietary spare parts and consumables creates a high-margin, low-marketing revenue tail: industry data shows aftermarket parts can carry gross margins of 50-70% and account for 20-40% of lifetime machine revenue, so each Freund machine sold typically yields multi-year secondary revenue with minimal acquisition cost.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margins: 50-70%\u003c\/li\u003e\n\u003cli\u003eShare of lifetime revenue: 20-40%\u003c\/li\u003e\n\u003cli\u003eLow marketing spend per sale\u003c\/li\u003e\n\u003cli\u003eMulti-year recurring cash flow per machine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Consulting and Training Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company monetizes deep expertise via consulting for process optimization and drug formulation, billing typical project fees of $50k-$300k and achieving ~25% gross margins on services in 2024.\u003c\/p\u003e\n\u003cp\u003eThey also charge per-person training fees ($1k-$6k) for on-site or in-house courses, adding recurring revenue that helped services reach 18% of total 2024 revenue and strengthens industry positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsulting projects: $50k-$300k\u003c\/li\u003e\n\u003cli\u003eTraining fees: $1k-$6k per person\u003c\/li\u003e\n\u003cli\u003eServices gross margin: ~25% (2024)\u003c\/li\u003e\n\u003cli\u003eServices share of revenue: 18% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund 2024: Equipment-led 75% sales, chemicals 58% (42% GM), services 18%, R\u0026amp;D 9%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund's 2024 revenue mix: capital equipment sales (0.5-5.0M per unit) drove ~75% of sales; specialty chemicals provided 58% of group revenue with ~42% gross margin; services (maintenance, parts, consulting, training) made up 18% of revenue, parts margins 50-70%, aftermarket ≈25-35% of machine lifetime revenue; R\u0026amp;D spend ≈9% (~$18M) of 2024 sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 %\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment sales\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003ctd\u003eUnit $0.5-5.0M; lead 6-18 mo; engineering fee 10-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemicals\u003c\/td\u003e\n\u003ctd\u003e58%\u003c\/td\u003e\n\u003ctd\u003eGross margin ~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices \u0026amp; parts\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eParts margin 50-70%; aftermarket 25-35% lifetime\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e9% of sales (~$18M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347052142923,"sku":"freund-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/freund-canvas-business-model.webp?v=1779138458","url":"https:\/\/valuechainanalysis.com\/products\/freund-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}